Crescendo Biologics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Crescendo Biologics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10869
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company’s pipeline includes humabody programs targeting oncology. It practises in the antibody discoveries and development, which include CAT, medimmune, morphosys and GSK. Crescendo develops a transformational Humabody-based topical biologic for psoriasis, which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The company’s oncology programmes produce novel therapeutics that capitalizes on advantages of the Humabody VH format. Crescendo is headquartered in Cambridge, the UK.

Crescendo Biologics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 12
Crescendo Biologics Raises US$3.3 Million In Series A Financing 13
Crescendo Biologics Raises US$28 Million In Series A Financing 14
Licensing Agreements 16
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 16
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 17
Crescendo Biologics Ltd – Key Competitors 18
Crescendo Biologics Ltd – Key Employees 19
Crescendo Biologics Ltd – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Jun 14, 2017: Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer 21
Apr 03, 2017: Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer 22
Other Significant Developments 23
Aug 15, 2018: Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 12
Crescendo Biologics Raises US$3.3 Million In Series A Financing 13
Crescendo Biologics Raises US$28 Million In Series A Financing 14
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 16
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 17
Crescendo Biologics Ltd, Key Competitors 18
Crescendo Biologics Ltd, Key Employees 19

List of Figures
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Crescendo Biologics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bando Chemical Industries Ltd (5195):企業の財務・戦略的SWOT分析
    Bando Chemical Industries Ltd (5195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • KION GROUP AG:企業の戦略・SWOT・財務情報
    KION GROUP AG - Strategy, SWOT and Corporate Finance Report Summary KION GROUP AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • Goodfellow Inc (GDL):企業の財務・戦略的SWOT分析
    Goodfellow Inc (GDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Centrica Plc (CNA)-石油・ガス分野:企業M&A・提携分析
    Summary Centrica plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Pear Therapeutics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Advance Syntex Ltd:企業の戦略的SWOT分析
    Advance Syntex Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Massilly Holding S.A.:企業の戦略・SWOT・財務分析
    Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report Summary Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Matrix IT Ltd (MTRX):企業の財務・戦略的SWOT分析
    Matrix IT Ltd (MTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BioTex Inc:企業の製品パイプライン分析
    Summary BioTex Inc (BioTex) operates as a medical device company that designs, develops, manufactures and distributes electro-mechanical, optical and software based devices. The company offers sterile and non-sterile disposable products for surgical, non-surgical and interventional procedures in dia …
  • Ascena Retail Group, Inc.:企業の戦略・SWOT・財務分析
    Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GVK Power and Infrastructure Ltd (GVKPIL):電力:M&Aディール及び事業提携情報
    Summary GVK Power and Infrastructure Ltd (GVKPIL), formerly Jegurupadu Operation & Maintenance Company Limited, is a diversified infrastructure company that operates across various sectors including energy, transportation, hospitality, resources, airports, and life sciences. It carries out construct …
  • AMAG Pharmaceuticals Inc (AMAG):医療機器:M&Aディール及び事業提携情報
    Summary AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history …
  • Impala Platinum Holdings Ltd:企業の戦略・SWOT・財務情報
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Exandal Corp:企業の戦略・SWOT・財務分析
    Exandal Corp - Strategy, SWOT and Corporate Finance Report Summary Exandal Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Atomstroyexport:企業の戦略的SWOT分析
    Atomstroyexport - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Furukawa Electric Co., Ltd.:企業の戦略・SWOT・財務情報
    Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bank Dhofar SAOG:企業の戦略・SWOT・財務分析
    Bank Dhofar SAOG - Strategy, SWOT and Corporate Finance Report Summary Bank Dhofar SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Axela Inc-医療機器分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆